Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer

Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer

Abstract Background Despite an enormous research effort, patients diagnosed with advanced colorectal cancer (CRC) still have low prognosis after surgical resection and chemotherapy. The major obstacle for CRC treatment is chemoresistance to front line anti-cancer drugs, such as 5-fluorouracil (5-FU)...

Full description

Bibliographic Details
Main Authors: Xianjun Sun, Wenhou Hou, Xin Liu, Jie Chai, Hongliang Guo, Jinming Yu
Format: Article
Language:English
Published: BMC 2020-12-01
Series:Cancer Cell International
Subjects:
REV7
TLS
5-FU
Oxaliplatin
Resistance
Colorectal cancer
Online Access:https://doi.org/10.1186/s12935-020-01668-z

Similar Items

Similar Items